193 related articles for article (PubMed ID: 34008214)
1. Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.
Meszaros M; Truchi R; Ouzan D; Tran A; Bourlière M; Pageaux GP
Hepatology; 2021 Oct; 74(4):2304-2306. PubMed ID: 34008214
[No Abstract] [Full Text] [Related]
2. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
Brown RS; Buti M; Rodrigues L; Chulanov V; Chuang WL; Aguilar H; Horváth G; Zuckerman E; Carrion BR; Rodriguez-Perez F; Urbánek P; Abergel A; Cohen E; Lovell SS; Schnell G; Lin CW; Zha J; Wang S; Trinh R; Mensa FJ; Burroughs M; Felizarta F
J Hepatol; 2020 Mar; 72(3):441-449. PubMed ID: 31682879
[TBL] [Abstract][Full Text] [Related]
3. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E;
J Hepatol; 2020 Mar; 72(3):431-440. PubMed ID: 31655134
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
Umemura M; Suda G; Tsukamoto S; Ebata K; Takahash S; Sasaki T; Nakajima S; Hirata K; Ozasa M; Takano M; Katagiri M; Sakamoto N
BMC Infect Dis; 2021 Apr; 21(1):389. PubMed ID: 33906643
[TBL] [Abstract][Full Text] [Related]
5. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
Reau N; Kwo PY; Rhee S; Brown RS; Agarwal K; Angus P; Gane E; Kao JH; Mantry PS; Mutimer D; Reddy KR; Tran TT; Hu YB; Gulati A; Krishnan P; Dumas EO; Porcalla A; Shulman NS; Liu W; Samanta S; Trinh R; Forns X
Hepatology; 2018 Oct; 68(4):1298-1307. PubMed ID: 29672891
[TBL] [Abstract][Full Text] [Related]
6. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
Wyles D; Poordad F; Wang S; Alric L; Felizarta F; Kwo PY; Maliakkal B; Agarwal K; Hassanein T; Weilert F; Lee SS; Kort J; Lovell SS; Liu R; Lin CW; Pilot-Matias T; Krishnan P; Mensa FJ
Hepatology; 2018 Feb; 67(2):514-523. PubMed ID: 28926120
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials.
Suleiman AA; Lin CW; Liu W; Eckert D; Mensing S; Burroughs M; Kato K; Chayama K; Kumada H; Oberoi RK
J Clin Pharmacol; 2020 Mar; 60(3):331-339. PubMed ID: 31515816
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
Fontana RJ; Lens S; McPherson S; Elkhashab M; Ankoma-Sey V; Bondin M; Dos Santos AGP; Xue Z; Trinh R; Porcalla A; Zeuzem S
Adv Ther; 2019 Dec; 36(12):3458-3470. PubMed ID: 31646465
[TBL] [Abstract][Full Text] [Related]
9. [A case of HCV genotype 3b with compensated stage cirrhosis who have two times treatment-experienced with the use of glecaprevir/pibrentasvir combined with sofosbuvir and ribavirin for 16 weeks].
Wang CY; Liu J; Wen J; Ma HX; Li J
Zhonghua Gan Zang Bing Za Zhi; 2021 Dec; 29(12):1194-1195. PubMed ID: 35045636
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China.
Pan S; Feng K; Huang P; Zeng Y; Ke L; Yang X; Liu J; Lin C
Medicine (Baltimore); 2021 Jun; 100(24):e26312. PubMed ID: 34128871
[TBL] [Abstract][Full Text] [Related]
11. Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
Poordad F; Pol S; Asatryan A; Buti M; Shaw D; Hézode C; Felizarta F; Reindollar RW; Gordon SC; Pianko S; Fried MW; Bernstein DE; Gallant J; Lin CW; Lei Y; Ng TI; Krishnan P; Kopecky-Bromberg S; Kort J; Mensa FJ
Hepatology; 2018 Apr; 67(4):1253-1260. PubMed ID: 29152781
[TBL] [Abstract][Full Text] [Related]
12. Reply to: "Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings".
Dietz J; Sarrazin C
J Hepatol; 2021 Jul; 75(1):254-255. PubMed ID: 33892009
[No Abstract] [Full Text] [Related]
13. Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea.
Shin HD; Song IH; Lee SH; Kim HS; Lee TH; Eun HS; Kim SH; Lee BS; Chae HB; Kim SH; Song MJ; Ko SY; Kim SB
Korean J Gastroenterol; 2024 Mar; 83(3):111-118. PubMed ID: 38522854
[TBL] [Abstract][Full Text] [Related]
14. A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
Sulkowski MS; Moon JS; Sherman KE; Morelli G; Darling JM; Muir AJ; Khalili M; Fishbein DA; Hinestrosa F; Shiffman ML; Di Bisceglie A; Rajender Reddy K; Pearlman B; Lok AS; Fried MW; Stewart PW; Peter J; Wadsworth S; Kixmiller S; Sloan A; Vainorius M; Horne PM; Michael L; Dong M; Evon DM; Segal JB; Nelson DR;
Hepatology; 2021 Dec; 74(6):2952-2964. PubMed ID: 34255381
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
Toyoda H; Chayama K; Suzuki F; Sato K; Atarashi T; Watanabe T; Atsukawa M; Naganuma A; Notsumata K; Osaki Y; Nakamuta M; Takaguchi K; Saito S; Kato K; Pugatch D; Burroughs M; Redman R; Alves K; Pilot-Matias TJ; Oberoi RK; Fu B; Kumada H
Hepatology; 2018 Feb; 67(2):505-513. PubMed ID: 28865152
[TBL] [Abstract][Full Text] [Related]
16. Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings.
Martin MT; Patel S; Kulik L; Chan C
J Hepatol; 2021 Jul; 75(1):251-254. PubMed ID: 33652031
[No Abstract] [Full Text] [Related]
17. Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.
Aragri M; Milana M; Di Maio VC; Lenci I; Carioti L; Perno CF; Svicher V; Angelico M; Ceccherini-Silberstein F
Clin Microbiol Infect; 2020 Sep; 26(9):1266-1268. PubMed ID: 32240711
[No Abstract] [Full Text] [Related]
18. [Glecaprevir/pibrentasvir in combination with ribavirin as salvage therapy in chronic hepatitis C].
Sánchez Suárez MM; Martín Roldán A; Cantudo Cuenca MR
Rev Esp Quimioter; 2024 Jun; 37(3):283-284. PubMed ID: 38638059
[No Abstract] [Full Text] [Related]
19. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
Kwo PY; Poordad F; Asatryan A; Wang S; Wyles DL; Hassanein T; Felizarta F; Sulkowski MS; Gane E; Maliakkal B; Overcash JS; Gordon SC; Muir AJ; Aguilar H; Agarwal K; Dore GJ; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
J Hepatol; 2017 Aug; 67(2):263-271. PubMed ID: 28412293
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
Stein K; Stoehr A; Klinker H; Teuber G; Naumann U; John C; Heyne R; Serfert Y; Niederau C; Zeuzem S; Berg T; Wiegand J;
Eur J Gastroenterol Hepatol; 2022 Jan; 34(1):76-83. PubMed ID: 32956186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
